Project Grant K99AI200654
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $889,519 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop multi-biologic, adeno-associated virus (AAV)-deliverable HIV-1 therapeutics for potential functional cure applications. The funded research advances AAV-vector delivery of broadly neutralizing antibodies and ECD4-IG, a potency and half-life...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $267,000 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory B cell function in transplant alloimmunity. The project examines whether neuropilin-2 (NRP2)-expressing B cell subsets promote immunoregulation and suppress CD4+ T effector cell activation in the context of organ transplant...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $160,609 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research targeting post-fusion influenza hemagglutinin to develop a more effective flu vaccine. The project runs through May 31, 2028, with place of performance in Boston, Massachusetts. The award is structured as a Project Grant, a competitive...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Boston University $815,378 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize high-affinity germline-encoded antibodies targeting viral pathogens that cause significant disease in infants and newborns. The recipient will immortalize naive B cell antibody repertoires from umbilical cord blood using yeast display technology and screen the resulting...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital) on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Overcoming Obstacles in Structural Elucidation of B Cell Antigen Receptor Assembly and Lateral Interaction," will be conducted through June 30, 2027, in Massachusetts. The research...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $1,032,783 to Massachusetts General Hospital on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on broadly neutralizing antibodies against HIV. The research, led by Dr. Alejandro Balazs at the Ragon Institute of MGH, MIT & Harvard, focuses on engineering the immune system through gene...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $727,080 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 1, 2026. The award funds investigation of age-specific mechanisms of action for three newly discovered adjuvant combinations using human in vitro models and age-specific in vivo models. The research addresses the burden of respiratory infections at extremes of...
- The National Institute of Allergy and Infectious Diseases awarded $864,475 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic structural and functional research on coronavirus spike proteins in membrane environments. The funded work examines distinct conformational states of membrane-bound spike proteins reconstituted in lipid bilayers, with focus...
- The National Institute of Allergy and Infectious Diseases awarded The Broad Institute, Inc. $165,269 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to direct the evolution of common human precursors into HIV-1 broadly neutralizing antibodies. The research addresses a critical gap in HIV vaccine development by focusing on the V2 apex epitope of the HIV-1 envelope glycoprotein. The project aims to develop practical immunization strategies that can move...
The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (Boston Children's Hospital) $159,300 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered B cells that prevent and control viral infections, beginning with HIV-1. The research develops a scarless method to engineer B cells to express human broadly neutralizing antibodies (BNAbs) against HIV-1. The work preserves key B-cell activities in vivo, including affinity maturation—the ability to generate higher-affinity antibody variants through competition for access to antigens. Aim 1 tests whether B cells expressing human BNAbs protect against HIV-like virus challenge and can adaptively control established infection, and whether engineered B cells accelerate decay of the viral reservoir compared to standard antiretroviral therapy. Aim 2 furthers enhancement of the engineered B-cell platform. Place of performance is Boston, Massachusetts. The period of performance runs through August 31, 2028. The award is a Project Grant, the standard NIH research grant mechanism for investigator-initiated biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $159.3k | 9/2/26 |